Gene test may personalize heart drug dosing
NCT ID NCT07439952
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how a person's genes affect their response to the heart drug mavacamten for obstructive hypertrophic cardiomyopathy. Researchers will collect DNA samples from 300 patients to see which genetic types respond best. The goal is to improve dosing safety and effectiveness based on genetic differences.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
APHP, Ambroise Paré
Boulogne-Billancourt, 92100, France
-
APHP, Bicêtre hospital
Le Kremlin-Bicêtre, France
-
APHP, La Pitié Salpetriere hospital
Paris, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New heart drug aficamten challenges standard Beta-Blocker in major trial
- Heart drug mavacamten under the microscope: Real-World study launches
- Heart drug mavacamten shows promise in Real-World study
- New pill aims to help heart patients breathe easier and move more
- Heart drug mavacamten under real-world safety watch in japan
- Could a common supplement help hearts pump better?